1. Determine the prognosis of breast cancer, TOP2A gene abnormalities in breast cancer patients predicts a shorter recurrence-free survival (RFS).
2. Guide clinical medication. Patients treated with TOP2A abnormalities have 65% lower risk of relapse using the CEF regimen than CM regimen, and the risk of death could be reduced by 67%; While TOP2A normal patients using CEF and CMF regimens’ curative effect is similar.